利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.03 秒)

    Antibodies to the C3d fragment of complement component 3
    4.
    发明授权
    Antibodies to the C3d fragment of complement component 3 有权

    公开(公告)号：US09815890B2

    公开(公告)日：2017-11-14

    申请号：US13805522

    申请日：2011-06-22

    申请人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik ,  Stephen Tomlinson

    发明人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik ,  Stephen Tomlinson

    IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  C07K14/47

    CPC分类号： C07K16/18 ,  C07K14/472 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

    Complement Receptor 2 Targeted Complement Modulators
    6.
    发明申请
    Complement Receptor 2 Targeted Complement Modulators 有权
    补体受体2靶向补体调节剂

    公开(公告)号：US20080267980A1

    公开(公告)日：2008-10-30

    申请号：US10534772

    申请日：2003-11-13

    申请人： Stephen Tomlinson ,  Michael V. Holers

    发明人： Stephen Tomlinson ,  Michael V. Holers

    IPC分类号： A61K39/00 ,  A61K38/16 ,  A61P35/00 ,  A61P29/00 ,  A61P31/00 ,  C07H21/00

    CPC分类号： C07K14/70596 ,  A61K38/00 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00

    摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

    摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。

    Tissue targeted complement modulators
    7.
    发明授权
    Tissue targeted complement modulators 失效
    组织靶向补体调节剂

    公开(公告)号：US08454963B2

    公开(公告)日：2013-06-04

    申请号：US11116939

    申请日：2005-04-28

    申请人： Stephen Tomlinson ,  Richard J. Quigg

    发明人： Stephen Tomlinson ,  Richard J. Quigg

    IPC分类号： A61K38/00 ,  C07K16/28 ,  C07K14/705

    CPC分类号： C07K14/70596 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00 ,  C07K2319/30

    摘要： Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

    摘要翻译： 补体系统的系统抑制已被证明是有效治疗炎性疾病，但是潜在的牺牲宿主防御和免疫稳态的代价。 本文公开的是用于补体抑制剂的抗原特异性靶向的方法，其显示针对近端肾小管上皮的补体抑制剂保护肾小管模型中的肾小管间质损伤和肾功能障碍。 已经表明，将系统给药的补体抑制剂适当靶向标记的疾病部位增强功效，并且避免需要系统地抑制补体。 另外，通过特异性抑制补体的末端途径显示，膜攻击复合物（MAC）在蛋白尿诱导的肾小管间质损伤中起关键作用，从而建立MAC作为蛋白质性疾病药理学干预的有效靶标。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。

    Complement receptor 1 and 2 fusion proteins
    9.
    发明授权
    Complement receptor 1 and 2 fusion proteins 有权
    补体受体1和2融合蛋白

    公开(公告)号：US08540997B2

    公开(公告)日：2013-09-24

    申请号：US13162434

    申请日：2011-06-16

    申请人： Stephen Tomlinson ,  V. Michael Holers

    发明人： Stephen Tomlinson ,  V. Michael Holers

    IPC分类号： A61K39/00

    CPC分类号： C07K14/70596 ,  A61K38/00 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00

    摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

    摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。

    Complement receptor 2 targeted complement modulators
    10.
    发明授权
    Complement receptor 2 targeted complement modulators 有权
    补体受体2靶向补体调节剂

    公开(公告)号：US08007804B2

    公开(公告)日：2011-08-30

    申请号：US10534772

    申请日：2003-11-13

    申请人： Stephen Tomlinson ,  V. Michael Holers

    发明人： Stephen Tomlinson ,  V. Michael Holers

    IPC分类号： A61K39/00 ,  C07H21/04

    CPC分类号： C07K14/70596 ,  A61K38/00 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00

    摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

    摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。